{
    "2019-04-04": [
        [
            {
                "time": "2018-11-05",
                "original_text": "Novartis, Amgen in dispute over migraine drug partnership",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Amgen",
                        "dispute",
                        "migraine",
                        "drug",
                        "partnership"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "Top Analyst Reports for Amazon, 3M & Novartis",
                "features": {
                    "keywords": [
                        "Analyst",
                        "Reports",
                        "Amazon",
                        "3M",
                        "Novartis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "industrials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-07",
                "original_text": "3 Ways to Buy Into the Marijuana Boom Without the Risk",
                "features": {
                    "keywords": [
                        "Marijuana",
                        "Boom",
                        "Risk"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-08",
                "original_text": "1 Biotech That Biogen Should Buy... but Probably Won't",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Biogen",
                        "Buy"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-09",
                "original_text": "Achillion Meets Enrollment Target in Kidney Disease Studies",
                "features": {
                    "keywords": [
                        "Achillion",
                        "Enrollment",
                        "Target",
                        "Kidney",
                        "Disease",
                        "Studies"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-10",
                "original_text": "Novartis Resubmits BLA to FDA for Biosimilar of Neulasta",
                "features": {
                    "keywords": [
                        "Novartis",
                        "BLA",
                        "FDA",
                        "Biosimilar",
                        "Neulasta"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-11",
                "original_text": "Novartis sues Amgen over migraine treatment Aimovig",
                "features": {
                    "keywords": [
                        "Novartis",
                        "sues",
                        "Amgen",
                        "migraine",
                        "treatment",
                        "Aimovig"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-12",
                "original_text": "Novartis CEO's $50 Billion of Deals Was Just the First Act",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "$50",
                        "Billion",
                        "Deals"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}